SCHEMBL7614129

SCHEMBL7614129

CCCCc1nc(SC)c(C(=O)OCC)n1Cc1ccc(-c2ccc(S(=O)(=O)NC#N)cc2C)cc1

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 5/20 0.49
AGTR1 P30556 4/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7611291 0.94 AGTR2 (0.49) AGTR2AGTR1
SCHEMBL7619991 0.92 AGTR2 (0.43) AGTR2AGTR1
SCHEMBL7608169 0.92 AGTR2 (0.50) AGTR2AGTR1
SCHEMBL7614343 0.92 AGTR2 (0.47) AGTR2AGTR1
SCHEMBL7614728 0.89 AGTR1 (0.48) AGTR2AGTR1
SCHEMBL8653526 0.88 AGTR2 (0.45) AGTR2AGTR1
SCHEMBL7612160 0.87 AGTR1 (0.64) AGTR2AGTR1
SCHEMBL7267772 0.87 AGTR1 (0.47) AGTR2AGTR1
SCHEMBL7616139 0.86 AGTR2 (0.43) AGTR2AGTR1
SCHEMBL7609786 0.86 AGTR2 (0.45) AGTR2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6335451-B1 ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2002-01-01 US claimed
US-6486189-B2 TREATMENT OR PROPHYLAXIS OF AN ILLNESS CAUSED BY AN ISCHEMIC CONDITION, OR FOR THE TREATMENT OF IMPAIRED RESPIRATORY DRIVE HOECHST AKTIENGESELLSCHAFT (DE) 2002-11-26 US disclosed
US-20020045761-A1 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them KLEEMANN HEINZ-WERNER (DE) 2002-04-18 US disclosed
US-6335451-B1 ANTIARRYTHMIA AGENTS, ANTIPROLIFERATIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045761-A1 Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them BAX, BCL2, TNNI3 AGTR2 1901/4885AGTR1 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.